Mark R. Hake

Mark R. Hake

CFA

Mark R. Hake, CFA is a financial analyst and entrepreneur. He has been a Chartered Financial Analyst (CFA) for 31 years and has owned his own investment management and investment research firms that focused on value stocks, both in the U.S. and overseas.

Mark writes over 600 articles per year on stocks, cryptos, SPACs, convertibles, ETFs, and other financial securities. He has been ranked with 5 stars by TipRanks.com (under “Mark R. Hake”) with an average return of over 22% annually and #36 out of 8,116 writers. Presently he authors articles on Medium.com and other sites.

Mark also invests in public and private equities and has acted as a hedge fund manager and portfolio manager for various money management firms. He has also acted as CFO and Chief Strategy Officer for several fin-tech and software companies.

You can follow Mark on LinkedIn and on TipRanks.

Recent Articles

Canoo Needs Capital And Shareholders Could Be Left Holding The Bag

By Mark R. Hake, CFA

Canoo will need more money within a year, so beware of buying its stock. GOEV could take a big hit as cash on hand dwindles if capital raises come later rather than sooner.

Now That Nokia Is Free Cash Flow Positive, Prospects for a Dividend Are High

By Mark R. Hake, CFA

The possibility of a Nokia dividend is now high. NOK stock could potentially pay 32.3 cents down the line, implying it could rise 29%.

Majorly Overvalued Microvision Stock Is Worse Than A Gamble

By Mark R. Hake, CFA

MicroVision is still up for sale but no one is going to buy MVIS stock at this high price. It will not be sold at a 60% higher price than its comps given that it has no comparable sales.

Ethereum Classic Is Risky, But It Might Be Better Than Ethereum

By Mark R. Hake, CFA

Ethereum Classic may be a long-term cheaper way to get into Ethereum, but there are risks. Ethereum Classic crypto has better performance features than Ethereum but also higher risks.

Zomedica Is Good Value and May Be Worth $1.36 — Or More

By Mark R. Hake, CFA

Zomedica is good value looks like it will go on the acquisition warpath. ZOM stock is worth between $1.11 and $1.61, or $1.36 on average, providing an average 20% ROI over 2 years.

The Fundamentals Behind Sundial Growers Just Don’t Add Up

By Mark R. Hake, CFA

Sundial Growers is a pile of cash and investments that doesn't add up. SNDL stock is now worth more than 57 cents per share at best, or 45% below its present price.

QuantumScape Needs to Change its Business Model to See Stock Gains

By Mark R. Hake, CFA

QS stock has barely moved and risks long-term stagnation unless QuantumScape makes drastic changes to bring in revenue.

AMC Stock Could Be Worth $80 On Its Own Merits

By Mark R. Hake, CFA

AMC stock may not be as overvalued as it seems -- it could be worth $80. AMC stock could be worth up to $79.72 under certain circumstances using an FCF model.

Chainlink Looks Like Good Value Here, Especially if Ethereum Takes Off

By Mark R. Hake, CFA

Chainlink crypto looks like good value here, especially if Ethereum takes off. LINK crypto will move up with Ethereum as its hybrid smart contract technology takes off.

7 Marijuana Stocks to Buy Now That Look Like Bargains

By Mark R. Hake, CFA

These marijuana stocks are absolute bargains. And they're poised to take off as cannabis becomes legal across the U.S.

Load More